AI Generated Image
For Narcoleptics, a 'New Chapter'
Newser • • health
Key Points:
- The FDA has approved Orzeyful, the first drug targeting the underlying biology of narcolepsy type 1 (NT1) by mimicking orexin, a brain chemical essential for wakefulness and muscle tone.
- Developed by Takeda, Orzeyful is a twice-daily oral medication that showed significant improvements in wakefulness, nighttime sleep, and reduction of cataplexy attacks in late-stage clinical trials involving 273 adults.
- No serious treatment-related side effects were reported during the trials, highlighting the drug's safety profile.
- Experts note that while Orzeyful represents a breakthrough for NT1 patients with orexin deficiency, some patients may require combination therapies due to varying underlying causes.
- Takeda emphasizes that Orzeyful’s approval could redefine narcolepsy management and potentially lead to orexin-based treatments for other disorders.
